Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion

In April 2024, the FDA also approved Alecensa as adjuvant treatment following tumour resection for patients with ALK-positive NSCLC (tumours ≥ 4 cm or node positive), as detected by an FDA-approved test. Sales of the Alecensa came in at CHF 355 million in the first quarter of 2024. Approval in the adjuvant treatment setting should boost demand for Alecensa for treating ALK-positive resectable NSCLC where there is a significant need for treatments. Roche's shares have lost 7.8% year to date against the indus ...